Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).

标题
Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 37, Issue 7_suppl, Pages 409-409
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2019-03-08
DOI
10.1200/jco.2019.37.7_suppl.409

向作者/读者发起求助以获取更多资源

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now